<DOC>
	<DOCNO>NCT01014091</DOCNO>
	<brief_summary>The objective study evaluate safety immunogenicity study GSK Biologicals ' pandemic influenza candidate vaccine ( GSK2340272A ) child age 3 9 year .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity GSK Biological Pandemic Candidate Influenza Vaccine ( H1N1 ) Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Children , male female , age 3 9 year time first study vaccination . Written inform consent obtain parent ( ) LAR ( ) subject . Healthy child , establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Clinically virologically confirm influenza infection within six month precede study start . Planned administration vaccine 30 day prior 30 day study vaccine administration . Have receive seasonal flu vaccine since last year . Previous administration H1N1 A/Californialike vaccine Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . For corticosteroid , mean prednisone &gt; = 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . History neurological disorder seizure . Acute disease and/or fever time enrolment : Fever define temperature &gt; = 37.5°C oral , axillary tympanic setting , &gt; = 38°C rectal setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . Any condition , opinion investigator , render subject unfit participation study . Child Care .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340272A</keyword>
</DOC>